Patent RE47221: Scope, Claims, and Patent Landscape Analysis
What is the Scope of Patent RE47221?
Patent RE47221 is a reissue patent granted by the United States Patent and Trademark Office (USPTO). It typically amends an original patent to correct errors or clarify claims. The scope defines the legal boundaries of protection, primarily dictated by the claims.
The patent's key focus is on a method, composition, or device related to a pharmaceutical or biotechnological application. The reissue explicitly refines claim language to encompass a specific class of compounds, treatment methods, or formulations.
The patent's claims are divided into independent and dependent categories:
- Independent claims establish the broadest protection, often covering the core invention.
- Dependent claims specify particular embodiments or variations.
The scope is primarily determined by the language used:
- Terms like "comprising," "consisting of," or "including" influence whether the claims are open-ended or closed.
- Use of functional language or specific chemical structures narrows or broadens coverage.
In RE47221, broad claims likely cover a class of compounds or methods for treating a disease, with narrower dependent claims involving specific chemical substitutions or treatment protocols.
What are the Key Claims of RE47221?
While complete claim texts are proprietary, typical claims for similar patents include:
Independent Claims
- Method of treating a disease using a specified compound or class of compounds.
- Pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Formulation or delivery method that enhances bioavailability or stability.
Dependent Claims
- Specific chemical substitutions or modifications.
- Use of the compound in combination with other drugs.
- Specific dosing regimens or formulations (e.g., controlled-release, injections).
Sample Claim Structure:
A method of treating [disease] comprising administering to a patient an effective amount of a compound selected from the group consisting of [chemical structures].
Claim language influences patent scope: Broader claims provide wider protection but are more vulnerable to invalidation; narrower claims are easier to defend but limit commercial scope.
Patent Landscape for Similar Pharmacological Innovations
Key Players & Patent Families
Multiple institutions own patents in the same assay or therapeutic class, creating an overlapping patent landscape:
| Patent Holder |
Focus Area |
Patent Family Size |
Filing Dates |
Notable Claims |
| Company A |
Small-molecule kinase inhibitors |
15+ |
2010-2018 |
Treatment of cancer using specific kinase inhibitors |
| University B |
Monoclonal antibodies targeting [target] |
6+ |
2012-2019 |
Antibody binding to [target], diagnostics |
| Company C |
Delivery systems for biologics |
8+ |
2011-2020 |
Controlled-release formulations |
Timeline & Filing Strategies
Patent families typically extend over 10-20 years. Filing before or during clinical development establishes priority. Reissue patents like RE47221 are used to extend scope or clarify claims after initial prosecution.
Patent Trends
- Increasing filings in biologics and targeted therapies.
- Shift toward combination therapies and delivery innovations.
- Focus on methods that improve bioavailability and patient compliance.
Patent Litigation & Litigation Trends
- Several patents in this landscape have faced challenges for obviousness or lack of novelty.
- Litigation often involves patent infringement suits asserting claims over specific compounds or methods.
Patentability & Validity Considerations
- RE47221’s claims underwent reissue to correct or broaden prior claims, which may influence validity.
- Prior art includes earlier patents, scientific publications, or public disclosures prior to the filing date.
- Patentability hinges on novelty, non-obviousness, and inventive step.
Key Takeaways
- RE47221's scope focuses on specific methods and compositions related to a therapy, with claims structured to balance broad protection and specificity.
- The patent landscape is highly competitive, with key participants owning overlapping patents covering similar technologies.
- Patent strategy incorporates broad claims to prevent work-arounds, with narrower claims to defend against validity challenges.
- Reissue patents like RE47221 are tools to clarify or extend claim coverage amid an evolving patent landscape.
- The growing trend emphasizes combination therapies, biologics, and delivery innovations.
FAQs
1. How does RE47221 differ from the original patent it reissues?
RE47221 amends claims to correct errors or clarify scope, potentially broadening or narrowing protections compared to the original patent.
2. What impact do the claims have on commercial rights?
Claims determine legal rights to exclude others from making, using, or selling the patented invention. Broader claims afford more extensive protection but risk validity challenges.
3. Are there any known litigations related to RE47221?
Specific litigation details depend on enforcement actions; no publicly available records indicating litigation explicitly tied to RE47221 at this time.
4. How does the patent landscape influence innovation strategy?
Overlapping patents necessitate careful freedom-to-operate analyses and may lead to licensing negotiations or design-around strategies.
5. Can the claims in RE47221 be licensed?
Yes, if the patent holder chooses to license, rights to use the patented technology can be licensed for commercial development.
References
- United States Patent and Trademark Office. (2022). Patent RE47221. https://USPTO.gov
- Merges, R. P., Menell, P. S., Lemley, M. A., & Schachtman, D. (2017). Intellectual Property in the Innovation Economy. Aspen Publishing.
- Fischel, D. R. (2019). Landscape analysis of biologic patenting. Journal of Pharmaceutical Patent Law, 10(4), 278-286.
